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Intensive  chemotherapy  followed  by  allogeneic  stem  cell  transplantation  (alloSCT)  can  cure  AML. Most
studies  on alloSCT  in  elderly  AML  report  results  of  highly  selected  patient  cohorts.  Hardly  any  data  exist
on  the  effectiveness  of  prospective  strategies  intended  to bring  as  many  patients  as  possible  to transplant.
Between  2006  and  2011  we  implemented  a treatment  algorithm  for  all  newly  diagnosed  AML  patients
aged  61–75  years,  consisting  of intensive  chemotherapy  cycles  to induce  complete  remission,  followed
by  alloSCT.  44  of  60 (73%)  newly  diagnosed  elderly  AML  patients  started  with  chemotherapy.  By meticu-
lously  following  our algorithm  in  almost  all patients,  we  could  induce  complete  remission  (CR)  in  66%  of
patients  starting  with  chemotherapy,  and  transplant  32%  of these  patients  in  continuous  CR.  Main  rea-
sons  for failure  were  early relapse  (16%),  early  death  (14%),  primary  refractory  disease  (9%), and  patient
or  physician  decision  to stop  treatment  (16%).  Patients  in  continuous  CR after  ﬁrst  induction  beneﬁt  most
with  36%  long-term  survival.  Patients  not  in  CR after  ﬁrst  induction  beneﬁt  less; although  additional
chemotherapy  induces  CR  in 45%  of  these  patients,  only  23%  are  transplanted  and no long-term  survival
is  observed,  mainly  due  to relapse.  Long-term  survival  in the  group of  44  patients  is 9% (median  4.5  years
after  alloSCT).  Considering  that  27%  of  patients  do not  start with  chemotherapy  and  64% of  patients  start-
ing  with chemotherapy  do not  reach  alloSCT,  the  reasons  for failure  presented  here  should  be  used  as a
guide  to develop  new  treatment  algorithms  to improve  long-term  survival  in elderly  AML patients.
©  2016  Elsevier  Ltd. All  rights  reserved.. Introduction
With a median age at diagnosis of 67 years, acute myeloid
eukemia (AML) predominantly affects the elderly [1]. Only 25%
f patients diagnosed with AML  are younger than 60 years [2].
uring the last 30 years, the prognosis of younger AML patients
as improved through the development of intensive chemother-
py regimens, better supportive care, and use of allogeneic stem cell
ransplantation (alloSCT), resulting in cure rates of 40–60% [2,3].In elderly AML  patients, intensive chemotherapy induces com-
lete remission in 40–60% [1]. Irrespective of performance status,
ML patients up to 80 years beneﬁt from intensive chemotherapy
∗ Corresponding author at: Dept. of Hematology, C2-R, Leiden University Medical
enter, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
E-mail address: P.A.von dem Borne@lumc.nl (P.A. von dem Borne).
ttp://dx.doi.org/10.1016/j.leukres.2016.03.010
145-2126/© 2016 Elsevier Ltd. All rights reserved.[3]. However, the survival advantage is short, and long-term sur-
vival has barely improved since 1970 in population-based studies
[2–4].
Feasibility studies on presumably highly selected patients
demonstrate curative potential of alloSCT in elderly AML  [5]. The
“real world” applicability of these results is unclear because hardly
any data exist on the efﬁcacy of sequential chemotherapy and
alloSCT in unselected AML  patient groups. In a prospective feasi-
bility analysis of alloSCT in AML  patients over 50 years, only 5.4%
of patients starting with chemotherapy reached alloSCT [6]. Data
on the applicability and especially on the reasons for failure of this
strategy in elderly AML  patients are urgently needed to facilitate
treatment decisions in this patient group to maximize the amount
of patients reaching alloSCT. These data are even more important
with the emergence of less toxic therapeutic agents such as azac-
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tidine and decitabine which can be used as alternative induction
reatments to reach alloSCT [7,8].
We  have developed a T cell-depleted reduced-intensity con-
itioning (TCD-RIC) alloSCT regimen with sequential pre-planned
onor lymphocyte infusion that has minimal early non-relapse
ortality (NRM) [9]. This regimen is tolerated well in elderly
atients up to the age of 75 years. Based on this alloSCT strategy, we
mplemented in 2006 a treatment algorithm for newly diagnosed
ML  patients aged 61–75 years. The operational goal of this algo-
ithm was to induce complete remission using sequential cycles
f chemotherapy in order to offer alloSCT in ﬁrst complete remis-
ion to as many patients as possible. Here we report the feasibility,
ffectivity, and reasons for failure of this strategy for all 60 consecu-
ive patients aged 61–75 presenting with AML  at Leiden University
edical Center between 2006 and 2011.
. Patients and methods
.1. Treatment strategy
The algorithm consisted of standard cytarabine-based intensive
nduction chemotherapy to induce a complete remission followed
y one cycle of remission consolidation chemotherapy, and TCD-
IC alloSCT. Complete remission was deﬁned in this report as
 blast percentage in the bone marrow aspirate below 5%. This
eﬁnition includes the categories complete remission (CR), com-
lete remission with incomplete recovery (CRi) and morphological
eukemia free state (MLFS) according to the European LeukemiaNet
riteria [10]. Patients not in complete remission after the induc-
ion chemotherapy were to be given a second course of induction
hemotherapy; if complete remission was achieved after second
nduction they could proceed with consolidation chemotherapy
nd transplantation.
.2. Allogeneic stem cell transplantation
HLA identical siblings or 10/10 HLA-A, B, C, DR and DQ matched
nrelated persons were used as donors for TCD-RIC alloSCT. The
onditioning regimen consisted of ﬂudarabine 50 mg/m2  PO for
 days, Busilvex 0.8 mg/kg IV 4 times daily for 2 days and T
ell depletion with either Thymoglobulin 14 mg/kg (3 patients),
lemtuzumab 30 mg  (4 patients) or alemtuzumab 30 mg  in com-
ination with Thymoglobulin 1 mg/kg (10 patients). In addition,
0 mg of alemtuzumab was directly added to the graft just prior
o infusion as additional graft-versus-host-disease prophylaxis.
o further immunosuppressive medications were given post-
ransplant. Donor lymphocyte infusion (DLI) was scheduled at 6
onths after alloSCT in case of persisting donor chimerism in the
one marrow mononuclear cell fraction. In case of high risk dis-
ase (very poor risk cytogenetics) donor lymphocyte infusion was
cheduled at 3 months after alloSCT. The Medical Ethics Committee
f the Leiden University Medical Center approved the transplanta-
ion regimen. Informed consent for transplantation was provided
n accordance with the Declaration of Helsinki.
.3. Analysis of data
All patients diagnosed with AML  between 2006 and 2011 aged
1–75 years were identiﬁed from the electronic Hospital patient
ocumentation system. Diagnostic information, treatment deci-
ions, and outcome were analyzed retrospectively. Data were
ollected in July 2015. SPSS was used for statistical analysis.a Research 46 (2016) 45–50
3. Results
Sixty elderly patients with newly diagnosed AML  presented to
our hospital from 2006 to 2011. The median age of patients was
68 years (range 61–75 years). Performance status was a median 1
(range 0–3; 3 patients with a performance status of 3). Cytogenet-
ics classiﬁed 59% of patients as intermediate risk. Sixteen and 23%
of patients had unfavorable or very unfavorable cytogenetic risk,
respectively. Only one patient belonged to a good risk category.
Sixteen of the 60 patients did not receive induction chemother-
apy. Reasons for withholding intensive chemotherapy were death
due to rapid deterioration (n = 2), patient decision (n = 5), physi-
cian recommendation (based on poor performance status and/or
comorbidity) (n = 7), or unknown (n = 2). Of the 44 patients
receiving induction chemotherapy (the intention-to-treat pop-
ulation), 31 patients (70%) were treated with MICE [11] and
13 (30%) patients with daunorubicin-cytarabine “3 + 7” [12] (see
also Supplementary Table). Seven patients received additional
gemtuzumab-ozogamicin or bevacizumab within experimental
arms of prospective trials; these protocols have failed to demon-
strate survival beneﬁt for these study drugs [11,12].
Eighteen patients (41%) were in complete remission (CR) after
the ﬁrst treatment cycle (Fig. 1). Of the remaining 22 patients that
failed to achieve remission, 15 were treated with the pre-planned
second induction chemotherapy, consisting of pulsed high-dose
cytarabine [13] in 5 patients, amsacrin-cytarabine [13] in 9 patients,
and MICE in 1 patient. Eleven patients achieved CR after the second
induction, resulting in an overall CR rate of 66% after one or two
induction cycles.
Four patients died during the ﬁrst cycle of chemotherapy; there-
fore day 30 mortality was 9.1%. An additional two patients died
shortly after day 30.
Twenty-three of the 29 patients (79%) in CR subsequently
received consolidation therapy (mini-ICE in 14 patients, pulsed
high-dose cytarabine in 4 patients, amsacrin-cytarabine in 4
patients, mitoxantrone-etoposide [13] in 1 patient). Four patients
received an additional consolidation cycle due to a lengthy donor
search.
The median survival of the 44 patients treated with intensive
chemotherapy was 330 days. In comparison, the 16 patients who
were ineligible for induction therapy had a signiﬁcantly inferior
outcome with a median survival of 118 days (Fig. 2A).
Fourteen patients underwent alloSCT in ﬁrst CR according to
the algorithm (32% of the intention-to-treat population). Two addi-
tional patients with an available stem cell donor were transplanted
in 1st CR without prior consolidation due to prolonged neutrope-
nia and a high likelihood for failure to repopulate after further
chemotherapy. Of the patients in CR after ﬁrst induction 61%
reached alloSCT in continuous CR. In contrast, a signiﬁcantly smaller
percentage of patients that were not in CR after ﬁrst induction
reached alloSCT (23%), despite the additional chemotherapy cycles
administered to these patients (p = 0.023, Fisher’s Exact test).
Absence of leukemic blasts in the bone marrow after the ﬁrst
induction cycle translated into improved survival when com-
pared to patients with persistence of leukemia (Fig. 2B). With a
median follow-up of 4.5 years after alloSCT, four patients (9% of
intention-to-treat population; 25% of per-algorithm population)
are still under follow-up in continuous remission. These long-term
survivors exclusively belonged to the group of 18 patients who
achieved CR after ﬁrst induction and their subgroup of 11 patients
who factually underwent alloSCT (Fig. 2C). Analysis of the whole
strategy of chemotherapy and alloSCT showed that a statistical sig-
niﬁcant difference exists between the 4 surviving patients of the
18 patients in CR after ﬁrst induction and the 0 surviving patients
of the 22 patients not in CR after ﬁrst induction (p = 0.033, Fisher’s
Exact test). Further analysis showed that in patients that were not in
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R after ﬁrst induction and were ultimately transplanted in CR, 80%
ied from relapse. In patients in CR after ﬁrst induction that were
ransplanted the rate of relapse was only 27% (3 of 11 evaluable
atients).
Eleven patients (25%) who did not experience an early relapse
fter induction did not undergo alloSCT (Fig. 1). These patients
herefore failed to follow the treatment algorithm for reasons other
han AML  persistence or on-therapy relapse. Treatment discontin-
ation predominantly occurred after induction 1 (n = 6; one patient
n CR) and after consolidation (n = 4). A severe bleeding event and
n infection in one case each were serious treatment complications
hat prevented treatment continuation. For one patient, no donor
ould be found. In seven cases, the patient or the treating physi-
ian felt that the burden of the scheduled subsequent treatment
teps could not be tolerated. All of these patients died eventually
n association with AML  persistence or relapse.
. Discussion
Feasibility studies have demonstrated the curative potential of
lloSCT in elderly AML  [5]. The “real world” applicability of these
esults is unclear because these studies most likely included highly
elected patients. Hardly any data exist on the efﬁcacy of sequential
hemotherapy and alloSCT in unselected AML  patient groups. Oneistered to the patient cohort.
large prospective feasibility analysis has been published in which
newly diagnosed AML  patients aged over 50 years receiving induc-
tion chemotherapy were evaluated at an early stage by transplant
physicians to maximize continuation to alloSCT [6]. In this study
only 5.4% of patients starting with chemotherapy reached alloSCT.
Major reasons for failure to reach alloSCT were non-evaluation by
the transplant physicians, unsuccessful donor search and unknown
reasons. Long-term survival was  mainly observed in transplanted
patients.
The 32% rate of patients reaching alloSCT in our study is con-
siderably superior to the 5.4% in the above mentioned prospective
feasibility analysis [6]. There are several possible reasons for this
difference. In contrast with the prospective feasibility analysis,
one team of physicians provides leukemia chemotherapy and
runs the allogeneic transplantation service in our center. There-
fore, every leukemia patient was evaluated for being a candidate
for alloSCT at diagnosis. Patients were given a second cycle of
induction chemotherapy if the ﬁrst cycle of induction chemother-
apy failed to induce remission. Patients achieving remission with
induction chemotherapy cycle were treated with a cycle of con-
solidation chemotherapy to deepen the remission. Patients in
continuous remission after consolidation chemotherapy were allo-
transplanted. By meticulously pursuing the algorithm, almost all
patients were treated according to the algorithm and reasons for
48 P.A. von dem Borne et al. / Leukemia Research 46 (2016) 45–50
F m. A: Overall survival of 44 patients receiving chemotherapy (solid line) and 16 patients
n lete remission (solid line) and not in complete remission (dashed line) after ﬁrst induction
c plete remission from ﬁrst induction to transplantation.
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Table 1
Reasons for failure of the algorithm.Reasons for not reaching alloSCT in patients
starting with intensive chemotherapy.
Relapse 16%
Early death 14%
Primary refractory disease 9%
Patient’s decision 9%
Physician’s decision 7%ig. 2. Survival curves of patients at different time points of the treatment algorith
ot  treated with chemotherapy (dashed line). B: Overall survival of patients in comp
hemotherapy cycle. C: Overall survival of patients transplanted in continuous com
ailure were recorded for all patients. The management of only 3
atients violated the algorithm. Two patients were transplanted
ithout prior consolidation chemotherapy due to prolonged neu-
ropenia and a high likelihood for failure to repopulate after further
hemotherapy; this decision was considered a medically man-
ated adaptation rather than non-adherence to the algorithm. One
atient relapsed just prior to the time point of transplantation and
as transplanted anyhow.
Because of the meticulous adherence to the treatment algo-
ithm, data gathered in this study represent real world data on the
esults that can be achieved when treating a cohort of elderly AML
atients with intensive chemotherapy to reach alloSCT. Although a
R was induced in 66% of the intention to treat patients, only 32%
f patients were eventually transplanted. Main reasons for failure
f the strategy were early relapse, early death, primary refractory
isease, and patient or physician decision to stop further treat-
ent (Table 1). Considering that 27% of patients did not start with
hemotherapy and 64% of patients starting with chemotherapy did
ot reach alloSCT, these reasons of failure may  be used as a guide to
ew treatment algorithms to improve long-term survival in elderly
ML patients.These data may  also be used as a comparison for determination
f the effectiveness of new less toxic therapeutic agents such as
zacitidine and decitabine that can be used as alternative induction
reatments to reach alloSCT [7,8]. Decitabine can induce completeNo donor found 2%
Bleeding/infection 5%
remissions in 30–40% of patients using a 10-day schedule [7] and
may  become an important alternative for intensive chemotherapy
in elderly patients, either alone or in combination with mitigated
chemotherapy. These alternative regimens should be tested in uns-
elected AML  patient groups as part of a strategy to reach alloSCT and
compared with the results obtained with chemotherapy strategy.
A major advantage of these alternative regimens might be that the
16 patients that were considered unﬁt for intensive chemotherapy
in our study (27% of all patients presenting to our hospital) could
also be offered a chance to reach alloSCT and achieve cure.
With six deaths during or shortly after the ﬁrst induction cycle
(14%), early mortality was  a major reason for on-algorithm treat-
ment failure (Table 1). Early death has been recognized as an
important problem in treating elderly AML  patients, and tools to
identify patients at high risk for early death have been developed
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14]. Application of these tools may  be used to guide patients to
reatment with alternative strategies.
Primary refractory disease and early relapse (together 25%) were
mportant reason for treatment failure in patients on the algo-
ithm. Early relapse may  for example be prevented by sequential
hemotherapy and transplantation into one treatment (as is per-
ormed in FLAMSA-RIC [15]), or by using maintenance therapy.
ecause a considerable number of patients decided to stop further
reatment, new therapeutic strategies in elderly patients should
im at a short time period between the start of treatment and
ransplantation.
A striking ﬁnding of our study is that long-term survival was only
bserved in the group of patients that achieved CR after the ﬁrst
nduction. Eleven patients that reached CR after the ﬁrst induction
ycle could be transplanted in continuous remission, of which four
ave remained long-term disease-free (36%) (Fig. 2C). The patients
ransplanted in continuous CR after ﬁrst induction (Fig. 2C) show
 survival percentage (36%) similar to results in many publica-
ions on alloSCT [16]. However, when these long-term survivors
re viewed within the context of the whole group of 44 intention
o treat patients (“AML in the real world”), it is clear there is much
oom for improvement by development of new treatment strate-
ies. This 9% survival at 5 years after start of therapy (4 out of 44
atients) is comparable with survival results found in population-
ased studies on elderly AML  patients [2,17,18], showing that our
trategy did not result in a survival advantage for the whole group
t this time point.
Especially the 22 patients that did not achieve a CR after the
rst induction cycle were found not to beneﬁt from our strat-
gy. Although we were able to induce CR in 45% of these patients
ith multiple chemotherapy cycles, only 23% were transplanted
signiﬁcantly less than the 61% of patients in CR after the ﬁrst
hemotherapy, reaching alloSCT in continuous remission (p = 0.023,
isher’s Exact test). However, no long-term survival was observed
fter transplantation (Fig. 2B). Main cause of death in these patients
as relapse during or shortly after chemotherapy cycles or relapse
fter transplantation (see Supplementary Table). On the basis of
hese results we think it is questionable to continue with stan-
ard chemotherapy in elderly AML  patients that are not in CR after
he ﬁrst induction cycle. For these alternative treatment strate-
ies should be developed. An alternative curative option after
rst induction failure could conceptually be achieved by efﬁca-
ious early cellular anti-leukemia interventions after alloSCT. In this
lderly and vulnerable patient group, such interventions should,
owever, not increase the risk of acute graft-versus-host disease.
The differences in clinical outcome after transplantation might
e caused by accidental differences in the type of transplantation.
he type of donor used did not affect outcome. Of the 16 patients
ransplanted in complete remission, 11 received stem cells from
n unrelated and 5 from a related donor; of the 11 patients trans-
lanted with an unrelated donor 3 survived long-term, of the 5
atients transplanted with a related donor 1 survived long-term.
ffects of pre-emptive DLI at 3 or 6 months after transplantation
lso did not appear to inﬂuence results. Six of 11 patients trans-
lanted after achieving a CR after ﬁrst induction (the group with 4
ong-term survivors) received pre-emptive DLI, of which one devel-
ped grade 1 and one grade 4 acute GVHD. Three of 5 patients
ransplanted after achieving a CR only after second induction (the
roup without long-term survivors) received pre-emptive DLI, of
hich one developed grade 1 and one grade 3 acute GVHD.
In well performing patients more intermediate and less unfavor-
ble/very unfavorable cytogenetic risk proﬁles were found (CR after
rst induction 6% unfavorable and 11% very unfavorable, trans-
lanted patients 12% unfavorable and 18% very unfavorable). In
atient groups performing worse (not in CR after ﬁrst induction) it
as the other way round (19% unfavorable and 31% very unfavor-a Research 46 (2016) 45–50 49
able). On the basis of these data it can be concluded that cytogenetic
risk proﬁles cannot predict patients failing or achieving CR after ﬁrst
induction or reaching transplant. The limited number of patients in
this study makes it impossible to draw any deﬁnite conclusions on
cytogenetic data.
Only one patient was  found to have a cytogenetic good risk pro-
ﬁle (core binding factor leukemia). This patient did not receive
an allotransplant, because a favorable survival effect has been
demonstrated in patients over 60 years treated only with intensive
chemotherapy [19]. However, this patient died from early relapse.
A similar favorable survival effect of intensive chemotherapy has
been shown in NPM1 positive FLT3 negative AML  [19]. Although
cytogenetic data were present in all patients, molecular diagnos-
tic data of the AML  were only present for a limited number of
patients. In all patients with long-term survival, molecular diag-
nostic data were either available or AML  material had been kept
for later testing. Three of these patients were NPM negative, one
was NPM positive and FLT3 negative, however this patient had a
leukocyte count of 150 × 10ˆ9/l at presentation. Using current risk
scores three long-term surviving patients would be poor risk and
one intermediate risk.
It is important to realize that we  did not perform any evaluations
of co-morbidities or geriatric assessments in this patient group
either at AML  diagnosis or at the time of alloSCT. Only performance
status was  used, which at AML  diagnosis should preferably be <=
2. Patients able to sustain two cycles of intensive chemotherapy
were considered ﬁt enough for non-myeloablative alloSCT. When
we started our strategy in 2006 little was known about the possibil-
ities of using co-morbidity and geriatric assessment tools to identify
patients suited for intensive chemotherapy and/or allogeneic stem
cell transplantation [14,20–23]. By using these tools, early death
after chemotherapy and transplantation related mortality can be
diminished.
One might argue that the T cell depleted alloSCT regimen
we use is not the best transplantation option for this patient
group and that the use of a T cell replete protocol might prevent
early relapses by graft-versus-host-disease and graft-versus-tumor
effects early after transplantation. We  decided to use a T cell
depleted regimen because elderly patients have limited tolerance
for graft-versus-host-disease. Many relapses occurred very early
after transplantation at the time point that tapering of immuno-
suppressive drugs would still take place in T cell replete protocols.
It is important to realize that approximately half of relapses
occurred already before transplantation. Considering the limited
graft-versus-host-disease tolerance in patients over 65 years of age,
we believe in further development of T cell depleted alloSCT regi-
mens in elderly AML  patients in combination with new strategies
to prevent early relapse.
In conclusion, despite the substantial drop-out rate and AML
resistance to chemotherapy, 32% of patients reached the pre-
speciﬁed milestones of CR after one or two induction cycles and
underwent alloSCT after consolidation therapy. Four of the eleven
patients who reached CR after the ﬁrst induction cycle and could
be transplanted in continuous remission have shown long-term
survival. This ﬁnding suggests a substantial chance of cure for
AML  patients between 60 and 75 years of age that are in com-
plete remission after ﬁrst induction chemotherapy and proceed
to alloSCT. Persistence of leukemia after the ﬁrst induction cycle
heralds treatment futility in our experience; for these patients,
alternative treatment strategies have to be developed.Acknowledgements
None.
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